

## ASX Code: NRT

Novogen Ltd

ABN 37 063 259 754

---

### Contact Details

PO Box 2333

Hornsby Westfield NSW 2077

T +61 2 9472 4100

F +61 2 9457 0388

E [Graham.Kelly@Novogen.com](mailto:Graham.Kelly@Novogen.com)

---

### Capital Structure

Ordinary Shares on issue:

168 M

---

### Board of Directors

#### Dr Graham Kelly

Chairman & Executive Director

#### Steve Coffey

Non Executive Director

#### John O'Connor

Non Executive Director

#### Ian Ross

Non Executive Director

#### Prof Peter Gunning

Non Executive Director

## ASX RELEASE

7 November 2014

### EXTENSION OF THE ASX BOOKBUILD FACILITY

Novogen today announces that the Closing Date of its current capital-raising using the ASX BookBuild Facility has been extended from today, Friday 7 November 2014 at 3 pm, to next **Tuesday 11 November 2014 at 3 pm.**

This is to allow adequate time to process the enquiries being fielded by the Company pursuant to yesterday's announcement and to finalise the placement.

The Company's securities will remain suspended until the offer closes next Tuesday, 11 November 2014.

Applications for stock will continue to be available through the ASX Bookbuild facility or through Novogen directly.

The settlement date will be on a T+4 basis, effectively on the 17 November 2014.

### About Novogen Limited

Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen Group includes a New Haven CT – based joint venture company, CanTx Inc., with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell's cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.

Further information is available on our websites [www.novogen.com](http://www.novogen.com)

For more information please contact:

**Investor Contact**

Dr. Graham Kelly  
Executive Chairman & CEO Novogen Group  
[Graham.Kelly@novogen.com](mailto:Graham.Kelly@novogen.com)  
+61 (0) 2 9472 4100

**Media Enquiries**

Cristyn Humphreys  
Operations Manager Novogen Group  
[Cristyn.Humphreys@novogen.com](mailto:Cristyn.Humphreys@novogen.com)  
+61 (0) 2 9472 4111

